Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURE: Sapropterin responsiveness in phenylketonuria over 28 days
2009-018168-81Phase 4Completed
- Sponsor
- Merck Serono
- Start
- Mar 2010
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sapropterin in phenylketonuria (PKU) and hyperphenylalaninemia (HPA), sponsored by Merck Serono. Primary endpoint: Proportion of sapropterin responders during 28 days. Started Mar 2010; status: completed.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)hyperphenylalaninemia (HPA)
Beyond the preview
Go deeper on 2009-018168-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018168-81.